Abstract: Capecitabine is currently the only novel, orally home-administered fl uorouracil prodrug. It offers patients more freedom from hospital visits and less inconvenience and complications associated with infusion devices. The drug has been extensively studied in large clinical trials in many solid tumors, including breast cancer, colorectal cancer, gastric cancer, and many others. Furthermore, the drug compares favorably with fl uorouracil in patients with such cancers, with a safe toxicity profi le, consisting mainly of gastrointestinal and dermatologic adverse effects. Whereas gastrointestinal events and hand-foot syndrome occur often with capecitabine, the tolerability profi le is comparatively favorable. Prompt recognition of severe adverse effects is the key to successful management of capecitabine. Ongoing and future clinical trials will continue to examine, and likely expand, the role of capecitabine as a single agent and/or in combination with other anticancer agents for the treatment of gastrointestinal as well as other solid tumors, both in the advanced palliative and adjuvant settings. The author summarizes the current data on the role of capecitabine in the management of gastrointestinal cancers.
Introduction
Fluoropyrimidines remain the standard treatment regimens for numerous types of solid tumors. Capecitabine (Xeloda ® , Hoffmann-La Roche Inc., Nutley, New Jersey, USA), a thymidine phosphorylase (TP)-activated fl uoropyrimidine carbamate, is the only universally approved orally administered fl uoropyrimidine. It belongs to a newer generation of orally administered fl uoropyrimidines. The clinical need for convenient, tolerable and effi cient agents that do not require continuous infusion like the original fl uorinated analog of uracil, 5-fl uorouracil (5-FU), prompted the development of capecitabine.
Chemistry 5-FU is not clinically useful when administered orally because extensive metabolism by dihydropyrimidine dehydrogenase (DPD) in the mucosa of the gastrointestinal tract and the liver leads to highly variable bioavailability. Capecitabine ( Figure 1 ) is an oral prodrug of 5-FU that is absorbed intact through the intestinal wall and then converted to 5-FU in three sequential enzymatic reactions. 1 The fi nal requisite enzyme, thymidine phosphorylase, is present at consistently higher levels in tumor rather than normal tissues, thereby suggesting that 5-FU delivered in this way may benefi t from an element of tumor targeting and thus enhanced selectivity and better tolerability. 2 Clinical evidence to support this comes from a study in patients with colorectal cancer. Capecitabine was administered 7 days before planned resection of the primary cancer and 5-FU levels assayed in tumor and adjacent tissues.
Saif
The median ratio of 5-FU concentration in colorectal tumors to adjacent tissues was 2.9 (range 0.9-8.0). 3 
Clinical pharmacology
Capecitabine is relatively non-cytotoxic in vitro and is readily absorbed from the gastrointestinal tract. In the liver, a 60 kDa carboxyesterase hydrolyzes much of the compound to 5'-deoxy-5-fl uorocytidine (5'-DFCR). Cytidine deaminase, an enzyme found in most tissues, including tumors, subsequently converts 5'-DFCR to 5'-deoxy-5-fl uorouridine (5'-DFUR). The enzyme thymidine phosphorylase (dThdPase) then hydrolyzes 5'-DFUR to the active drug 5-FU. Many tissues throughout the body express thymidine phosphorylase 4 and some human carcinomas including adenocarcinomas of the pancreas express this enzyme in higher concentrations than surrounding normal tissues. 5 Both normal and tumor cells metabolize 5-FU to 5-fluoro-2-deoxyuridine monophosphate (FdUMP) and 5-fl uorouridine triphosphate (FUTP). These metabolites cause cell injury by two different mechanisms. Firstly FdUMP and the folate cofactor, N5-10-methylenetetrahydrofolate, bind to thymidylate synthase (TS) to form a covalently bound ternary complex. This binding inhibits the formation of thymidylate from 2'-deaxyuridylate. Thymidylate is the necessary precursor of thymidine triphosphate, which is essential for the synthesis of DNA, so that a defi ciency of this compound can inhibit cell division. Secondly nuclear transcriptional enzymes can mistakenly incorporate FUTP in place of uridine triphosphate (UTP) during the synthesis of RNA. This metabolic error can interfere with RNA processing and therefore protein synthesis.
Pharmacokinetics and metabolism
The pharmacokinetics of capecitabine and its metabolites have been evaluated in a number of studies over a dosage range of 500 to 3500 mg/m 2 /day. 3 Over this range the pharmacokinetics of capecitabine and its metabolite, 5'-DFCR, were linear and did not alter with time. The increases in the areas under curves (AUCs) of 5'-DFUR and 5-FU, however, were greater than proportional to the increase in dose and the AUC of 5-FU was 34% higher on day 14 than on day 1. The elimination half-life of both parent capecitabine and 5-FU was about 45 minutes. The inter-patient variability in the C max and AUC of 5-FU was greater than 85%. Capecitabine reached peak blood levels (T max ) in about 1.5 hours with peak 5-FU levels occurring slightly later, at 2 hours. Food reduced both the rate and extent of absorption of capecitabine with mean C max and AUC decreased by 60% and 35%, respectively. The C max and AUC of 5-FU were also reduced by food by 43% and 21%, respectively. Food delayed T max of both parent and 5-FU by 1.5 hours. Plasma protein binding of capecitabine and its metabolites is less than 60% and is not concentration-dependent. Capecitabine was primarily bound to human albumin (approximately 35%). Capecitabine is extensively metabolized enzymatically to 5-FU ( Figure 2 ). The enzyme dihydropyrimidine dehydrogenase (DPD) hydrogenates 5-FU to the much less toxic 5-fl uoro-5,6-dihydro-fl uorouracil (FUH2). Dihydropyrimidinase cleaves the pyrimidine ring to yield 5-fl uoro-ureido-propionic acid (FUPA). Finally beta-ureido-propionase cleaves FUPA to alfa-fl uoro-beta-alanine (FBAL) which is cleared in the urine. Capecitabine and its metabolites are predominantly excreted in urine; 95.5% of administered capecitabine dose is recovered in urine. 6 Fecal excretion is minimal (2.6%). The major metabolite excreted in urine is FBAL which represents 57% of the administered dose. About 3% of the administered dose is excreted in urine as unchanged drug.
Capecitabine has been evaluated in patients with mild to moderate hepatic dysfunction due to liver metastases defi ned by a composite score including serum levels of bilirubin, aspartate and alanine transaminases and alkaline phosphatase. 7 Following a single 1255 mg/m 2 dose of capecitabine both AUC and C max of capecitabine increased by 60% compared to patients with normal hepatic function (n = 14). Although the AUC and C max of 5-FU was not affected capecitabine should be administered with caution in patients with even mild hepatic dysfunction and avoided in the presence of more severe liver impairment. There does not appear to be an effect on the pharmacokinetics of capecitabine or 5-FU with declining creatinine clearance but levels of 5-DFUR and FBAL do rise signifi cantly once the creatinine clearance falls by more than 50%. 
Drug interactions
In vitro enzymatic studies with human liver microsomes indicated that capecitabine and 5'-DFUR had no inhibitory effects on substrates of cytochrome P450, suggesting a low likelihood of interactions with drugs metabolized by cytochrome P450 enzymes. However an important interaction exists between capecitabine and warfarin, resulting in exaggerated anticoagulant activity and requiring close monitoring of the INR if these drugs are co-administered. 9 The exact mechanism of the interaction is uncertain. An additional interaction occurred when Maalox ® (20 mL), an aluminium hydroxide-and magnesium hydroxide-containing antacid, was administered immediately after capecitabine (1250 mg/m 2 ). AUC and C max increased by 16% and 35%, respectively for capecitabine and by 18% and 22%, respectively, for 5'-DFCR. No effect was observed on the other three major metabolites (5'-DFUR, 5-FU, FBAL) of capecitabine.
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Summary of safety and tolerability
Capecitabine is relatively non-cytotoxic in vivo and thus the toxicity profi le refl ects that of its active metabolite 5-FU. The toxicity of 5-FU is known to be schedule-dependent. Bolus 5-FU causes mainly diarrhea, oral mucositis, myelosuppression and ocular irritation while infusional schedules may cause hand-foot syndrome (HFS) and ulcers on the lips but rarely result in signifi cant myelosuppression. Interestingly the toxicity of capecitabine lies somewhere between that of bolus and infusional 5-FU. 11 Diarrhea occurs in up to 50% of patients and may be severe, requiring hospital admission for intravenous (iv) fl uids and antibiotics if accompanied by neutropenia. About half the patients treated will also develop a degree of HFS which may be helped by the use of pyridoxine (vitamin B6). Many patients indicate that fatigue is often the most disruptive side effect of all and this may continue for some time after treatment has ended. Diarrhea occurs in around half the patients who receive capecitabine. This can be quite severe but is usually well controlled with medication. Mouth ulcers may occur and nausea and/or vomiting affect 30% of patients but is readily controlled with antiemetics. Occasional side effects include constipation, headaches, conjunctivitis, anorexia, abdominal pain, hair thinning, ankle swelling and chest pain due to coronary vasospasm.
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Clinical activity
Capecitabine is currently approved by the FDA for use as fi rst-line therapy in patients with metastatic colorectal cancer when single-agent fl uoropyrimidine therapy is preferred. The drug is also approved for use as a single agent in metastatic breast cancer patients who are resistant to both anthracyclineand paclitaxel-based regimens or in whom further anthracycline treatment is contra-indicated and in combination with docetaxel after failure of prior anthracycline-based chemotherapy. 13 Single-agent and combination regimens have also shown benefi ts in patients with prostate, pancreatic, renal cell, and ovarian cancers. Improved tolerability and comparable effi cacy compared with iv 5-FU/LV (5-FU with leucovorin) in addition to oral administration make capecitabine an attractive option for the treatment of several types of cancers as well as the focus of future trials.
Colorectal cancer
For more than 40 years, 5-FU has been the foundation treatment for metastatic colorectal cancer and has been used with LV or in combination with irinotecan or oxaliplatin. As fi rst-line therapy in colon cancer patients capecitabine has been studied either as single-agent administration compared directly to iv 5-FU/LV in two large randomized phase III trials 14 or in combination with irinotecan 15, 16 and oxaliplatin [17] [18] [19] [20] in non-comparative studies. In the adjuvant setting a large randomized phase III trial (X-ACT study), enrolling 1987 Dukes C colon cancer patients, was conducted comparing single-agent capecitabine administration with iv 5-FU/LV (Mayo Clinic regimen). [21] [22] [23] In the fi rst-line monotherapy setting, the two randomized, prospective phase III trials enrolled a total number of 1207 patients, who were randomized to receive either oral 24,25 ( Figure 3 ). Capecitabine demonstrated a statistically signifi cant superior objective response rate (ORR) compared with 5-FU/LV (26% vs 17%; p Ͻ 0.0002), even in a patient subpopulation with poor prognostic parameters. Time to progression (TTP) was equivalent in both arms (4.6 vs 4.7 months; p = 0.85) and the same was revealed for overall survival (OS) (12.9 vs 12.8 months; p = 0.48). 51 As far as the safety profi le was concerned, all-grade AEs, including diarrhea (47.7% vs 58%; p Ͻ 0.001), stomatitis (24.3 vs 61.6%; p Ͻ 0.001), nausea (87.9 vs 47.6%; p Ͻ 0.001), alopecia (5 vs 20.6%; p Ͻ 0.001) and neutropenia requiring medical intervention (1.2% vs 10.5%; p Ͻ 0.001) occurred signifi cantly more frequently in the 5-FU/LV arm. HFS was the only AE occurring in signifi cantly higher incidence with capecitabine (55.5% vs 62%; p Ͻ 0.001). In addition, grade 3/4 stomatitis (2% vs 14.7%; p Ͻ 0.001) and grade 3/4 neutropenia (2.3% vs 22.8%; p Ͻ 0.001) resulting in a signifi cantly higher incidence of neutropenic fever and sepsis (0.2% vs 3.4%, p Ͻ 0.001), were more frequently observed with 5-FU/LV, whereas grade 3 HFS (17.1 vs 0.7%) occurred more frequently with capecitabine. Grade 3 hyperbilirubinemia appeared more frequently (18.3% vs 3.3%; p Ͻ 0.001) in the capecitabine group but tended to be an isolated phenomenon involving only indirect bilirubin. Recently, a meta-analysis of the medical resource used in one of the trials demonstrated that single-agent capecitabine as monotherapy treatment for advanced, metastatic colorectal cancer, apart from being effi cient and more tolerable than 5-FU/LV, also led to substantial reduction in medical resource use. 26 Capecitabine has been also evaluated as fi rst-line treatment in metastatic colorectal cancer patients in combination either with oxaliplatin [17] [18] [19] [20] or with irinotecan 15, 16 in non-comparative phase II studies. When administered in combination with oxaliplatin (120 mg/m 2 on day 1 or 70 mg/m 2 on days 1 and 8), the dose of capecitabine varied between 750 mg/m 2 bid and 1250 mg/m 2 on days 1-14 followed by 7 days rest in a 3-week cycle. [19] [20] [21] [22] Capecitabine has been also evaluated as fi rst-line treatment in metastatic colorectal cancer patients in combination either with oxaliplatin [15] [16] [17] [18] [19] or with irinotecan [19] [20] [21] [22] in phase II-III studies. When administered in combination with oxaliplatin (130 mg/m 2 on day 1 or 70 mg/m 2 on days 1 and 8), the dose of capecitabine varied between 750 mg/m 2 bid and 1250 mg/m 2 on days 1-14 followed by 7 days rest in 3-week cycle. [19] [20] Cassidy et al reported a two-arm, randomized, noninferiority, phase III study (XELOX-1; NO16966A) comparing XELOX with FOLFOX-4 in the fi rst-line treatment of MCRC. 27 After the pivotal phase III data for bevacizumab became available 28 the protocol was amended to a randomized, 2 × 2 factorial design with two coprimary objectives. The intent-to-treat population comprised 634 patients from the original two-arm portion of the study, plus an additional 1400 patients after the start of the amended 2 × 2 design, for a total of 2034 patients. The median PFS was 8.0 months in 28 The main reasons for discontinuation were diarrhea 28 and sensory neuropathy. In only one study did the initial dose of capecitabine have to be modifi ed from 1000 mg/m 2 bid to 750 mg/m 2 bid, because of the high incidence (85%) of diarrhea.
When administered concurrently with irinotecan, the dose of capecitabine ranged from 1000 mg/m 2 to 1250 mg/m 2 bid on days 1-14 followed by 1 week rest for 21 days, while irinotecan was delivered at dose 240 mg/m 2 to 300 mg/m 2 on day 1 or 100 mg/m 2 to 150 mg/m 2 on days 1 and 8 in 3-week cycles. 15, 16, 29, 30 In the study conducted by Bajetta et al 16 The ORR in all studies ranged from 42% to 49%, which is similar to the results previously reported with FOLFIRI. 30, 32 The most common grade 3/4 AEs were diarrhea (19%-27%), neutropenia (11%-12%) and nausea/vomiting (10%-12%). In all studies, the incidence of grade 3 HFS secondary to capecitabine was lower compared with the one experienced with capecitabine alone. Although no comparative trial was performed, grade 3/4 neutropenia occurred less frequently (11%-12% vs 46%) than with FOLFIRI, whereas the incidence of grade 3/4 diarrhea was higher. Both capecitabine combinations either with oxaliplatin or with irinotecan revealed comparable effi cacy with FOLFOX4 and FOLFIRI, respectively, with acceptable safety and tolerability. The results of ongoing randomized comparative phase III trials will ascertain the future of these combinations in the fi rst-line treatment of colorectal cancer. In the adjuvant setting, capecitabine has been administered either as monotherapy or in combination with oxaliplatin. In a randomized, multicenter, comparative phase III trial (X-ACT) 1987 Dukes C resected colon cancer patients were randomized to receive as adjuvant treatment either single-agent capecitabine (1250 mg/m 2 bid days 1-14 every 21 days [n = 1004]) or the Mayo Clinic regimen (LV 20 mg/m 2 iv followed by bolus iv administration of 5-FU, 425 mg/m 2 on days 1-5 every 28 days, [n = 983]) over a period of 24 weeks. 33 The X-ACT study demonstrated a signifi cantly superior relapse-free survival (p = 0.053) and trends toward superior disease-free survival (p = 0.053) and OS (p = 0.071) for the capecitabine arm (Figure 4) . In addition, a positive safety profi le was observed with capecitabine, producing signifi cantly less of all grades of diarrhea (46 vs 64%; p Ͻ 0.001), nausea/vomiting (36% vs 51%; p Ͻ 0.001), stomatitis (22% vs 60%; p Ͻ 0.001), alopecia (6% vs 22%; p Ͻ 0.001) and neutropenia (32 vs 63%; p Ͻ 0.001) ( Figure 5 ). HFS was more frequently observed (60% vs 9%; p Ͻ 0.001) with capecitabine. In addition, grade 3/4 neutropenia (2% vs 26%; p Ͻ 0.001) leading to febrile neutropenia and consequently to sepsis (0.3% vs 3%; p Ͻ 0.001), and stomatitis, (2% vs 14%; p Ͻ 0.001) were signifi cantly more common in the 5-FU arm. Grade 3 hyperbilirubinemia (Ն3 times the upper limit of normal) was more common with capecitabine (18% vs 5.9%). The incidence of grade 3/4 abnormalities of the hepatic enzymes (serum glutamic-oxoacetic transaminase, serum glutamate-pyruvate transaminase), however, was low in both treatment arms (0.7% and 1.6%, respectively, with capecitabine, and 0.3% and 0.6%, respectively, with 5-FU/LV).
The safety profile of capecitabine was similar, regardless of patients' age (Ͻ65 or Ն65 years of age). The incidence of fi rst and second dose reduction was higher in patients receiving 5-FU/LV (42% and 13%, respectively, for capecitabine, and 44% and 26%, respectively, for the latter). In addition, median time to fi rst and second dose reduction was longer with capecitabine, compared with 5-FU/LV (78 and 113 days, respectively, for capecitabine, and 41 and 57 days, respectively, with 5-FU/LV). Premature withdrawal was infrequent in both treatment arms (16 vs 12%). These results led the FDA to approve capecitabine as single-agent adjuvant therapy for Dukes C colon cancer patients, when single fl uoropyrimidine therapy is preferred.
In another randomized phase III trial in Dukes C colon cancer patients, three arms of adjuvant chemotherapy were compared: XELOX (capecitabine at dose 1000 mg/m stomatitis (0.6% vs 11.2% vs 0%, respectively) were less frequently observed with XELOX than with other treatment arms. Grade 3 HFS (3.6% vs 0.2% vs 0.2%, respectively), sensory neuropathy (8.1% vs 0 vs 0%), and vomiting (5% vs 1.7% vs 4.6%) occurred more frequently with XELOX compared with the other two arms. The incidence of grade 3/4 diarrhea was approximately the same with XELOX and the Mayo Clinic regimen (15% vs 13.5%, respectively), but higher with Roswell Park regimen (26.2%). Early safety results of XELOX administration are comparable with those of the FOLFOX regimen, the standard adjuvant therapy for colon cancer patients. 35 Effi cacy results will be available in 2008.
The proven effi cacy and safety benefi ts of capecitabine over iv 5-FU/LV in the treatment of metastatic and early stage colon cancer have led to the development of a number of studies evaluating the use of capecitabine in chemoradiation schedules for patients with locally advanced rectal cancer (LARC) as single agent as well as in combination with oxaliplatin or irinotecan. Although several dosing and schedule protocols of single-agent capecitabine combined with radiotherapy for locally advanced rectal cancer patients have been evaluated in several noncomparative phase II trials, [36] [37] [38] [39] [40] the continuous administration of capecitabine at a dose of 825 mg/m 2 bid concurrently with radiotherapy was the most applied. We retrospectively compared the safety and effi cacy of capecitabine-based regimens with well-established CIV-5-FU-based (continuous intravenous infusion 5-FU) regimens in LARC. 41 We collected published data on 542 patients treated on either CIV-5-FU (197) or capecitabine (345) with concurrent radiation (external radiation treatment, XRT) for LARC. This included phase I or II studies published or available from Pubmed. Safety was assessed by determining proportion of patients who experienced grade III/IV adverse effects. Effi cacy was assessed by determining pathological complete response (pCR). Chi-square tests were used to compare the two regimens. A p value less than 0.05 was considered statistically signifi cant. Statistical tests were further corrected for multiplicity using the method of Benjamini and Yekutieli. We found that pCR was signifi cantly higher in patients getting capecitabine vs CIV-5-FU (25 vs 13%; p = 0.008, P [adj] = 0.034). Both regimens were generally well tolerated. There was no grade IV toxicity reported. Grade III HFS was more common in the capecitabine group, and grade III diarrhea was more common in the CIV group. Capecitabine appears to be tolerable, with no reported grade 4 AEs in most studies, and low incidence of grade 3 toxicities. Additionally, it is more convenient than protracted infusion of 5-FU and demonstrates comparable effi cacy achieving satisfactory tumor down-staging rates and pathological response rates. The same observation was made for concurrent administration of XELOX and XELIRI with radiotherapy. [42] [43] [44] [45] [46] [47] In light of the encouraging results, two large randomized phase III trials are in progress. The National Surgical Adjuvant Breast and Bowel Project R-04 trial is recruiting patients to receive either radiotherapy plus capecitabine ± oxaliplatin or plus infusional 5-FU ± oxaliplatin. Following surgery, patients will be administered FOLFOX ± bevacizumab. The Pan-European Trials in Adjuvant Colorectal Cancer 6 trial compares neoadjuvant capecitabine plus radiation followed by adjuvant capecitabine with or without oxaliplatin.
Gastric or gastroesophageal cancer
Capecitabine is being investigated in phase I-III trials for the treatment of gastric, gastroesophageal, and esophageal cancers, both in the fi rst-line metastatic setting as well as in the adjuvant setting. The most frequently investigated combinations include capecitabine with docetaxel, paclitaxel, cisplatin, or oxaliplatin, and irinotecan. These therapies have yielded effi cacy data that compare favorably with data from phase III trials of parenteral 5-FU in the fi rst-line metastatic setting, and they mostly are well tolerated.
A phase III study evaluated XP (capecitabine/cisplatin) vs FP (5-FU/cisplatin) in fi rst-line in patients with previously untreated measurable advanced gastric cancer. 48 The patients received either oral capecitabine (1000 mg/m 2 bid days 1-14) + cisplatin (80 mg/m 2 iv day 1) q3w (XP arm) or 5-FU (800 mg/m 2 /day continuous infusion, days 1-5) + cisplatin (80 mg/m 2 iv day 1) q3w (FP arm). XP requires 1 day per 3 weeks in hospital; FP requires 5 days. Patients were treated until disease progression or unacceptable toxicity. Primary endpoint was non-inferiority (NI) in progression-free survival (PFS), defi ned as upper limit of 95% confi dence interval (CI) of hazard ratio (HR) Ͻ1.4 (fi rst test) and Ͻ1.25 (second test). Preliminary results presented at the annual meeting of ASCO 2006 showed that 316 patients were enrolled in 13 countries (Table 1) . Both arms were well balanced. The primary endpoint was met: capecitabine plus cisplatin was noninferior to fl uorouracil plus cisplatin in terms of progression-free survival (HR 0.81 [95% CI 0.63, 1.04]). The most common treatment-related grade 3/4 AEs (XP vs FP) were: neutropenia (16% vs 19%), vomiting (7% vs 9%), stomatitis (2% vs 7%), diarrhea (5% vs 5%), and anemia (5% vs 3%). The rate of all-grade HFS was low (22% vs 4%). These fi ndings suggest that capecitabine should become the fl uoropyrimidine of choice for advanced gastric cancer, given the effi cacy, reduced hospitalization time and simplifi ed regimen.
In another phase III trial (REAL-2) 1002 patients were randomly assigned to receive triplet therapy with epirubicin and cisplatin plus either fl uorouracil (ECF) or capecitabine (ECX) or triplet therapy with epirubicin and oxaliplatin plus either fl uorouracil (EOF) or capecitabine (EOX). 49 The primary end point was noninferiority in OS for the triplet therapies containing capecitabine as compared with fl uorouracil and for those containing oxaliplatin as compared with cisplatin. For the capecitabine-fl uorouracil comparison, the hazard ratio for death in the capecitabine group was 0.86 (95% CI, 0.80-0.99); for the oxaliplatin-cisplatin comparison, the HR for the oxaliplatin group was 0.92 (95% CI, 0.80-1.10). Median survival times in the ECF, ECX, EOF and EOX groups were 9.9 months, 9.9 months, 9.3 months and 11.2 months, respectively; survival rates at 1 year were 37.7%, 40.8%, 40.4% and 46.8%, respectively. In the secondary analysis, OS was longer with EOX than with ECF, with a hazard ratio for death of 0.80 in the EOX group (95% CI, 0.66 to 0.97; p = 0.02). PFS and response rates did not differ signifi cantly among the regimens. Toxic effects of capecitabine and fl uorouracil were similar. Current studies are evaluating the effi cacy of capecitabine in combination with other agents, including oxaliplatin as well as in combination with radiation therapy. 50 
Pancreatic cancer
Initial phase II trials suggested that capecitabine had useful activity in pancreas cancer. A phase II trial by Cartwright et al investigated the safety and effi cacy of capecitabine in 42 patients with advanced or metastatic pancreatic cancer. These patients received capecitabine monotherapy (1250 mg/m 2 twice daily on days 1-14 of a 21-day cycle). 51 The safety profi le of capecitabine was similar to that observed with capecitabine in colorectal and breast cancer. The major grade 3/4 adverse events were diarrhea, HFS and nausea. There were three confi rmed partial responses (7%) and a further 17 patients (41%) achieved stable disease as their best response (including disease stabilization for 12 weeks in 11 patients [26%]). The median duration of response was 2.8 months and the median OS was 6.0 months. In addition 10 patients (24%) achieved a positive Clinical Benefi t Response score and pain intensity was reduced in a further 12 patients (29%).
As a result of pre-clinical evidence to suggest that capecitabine was synergistic with gemcitabine 52 the combination went on to be tested in clinical trials. A multinational randomized trial by Herrmann et al reported no advantage of adding capecitabine, however subgroup analysis showed the benefi t for GemCap in patients with good performance status (HR 0.76; p Ͻ 0.03). 53 Another phase III randomized trial by Cunningham et al that compared single-agent gemcitabine with gemcitabine weekly for 3 weeks plus capecitabine 1660 mg/m 2 daily for 21 days every 28-day cycle. 54 Addition of capecitabine doubled response rate (14% vs 7%; p = 0.008) and improved OS (HR 0.80; p = 0.026). Myelosuppression was higher in incidence with the combination arm and HFS was only noted in combination arm. There have been three negative phase III trials of gemcitabine plus a fl uoropyrimidine: "Why is this one positive?" The fi nal results of the study are anxiously awaited to answer this question.
Recently, fi nal results of the phase II study of gemcitabine, capecitabine, and bevacizumab in patients with advanced pancreatic cancer have been presented. 55 Patients received bevacizumab 15 mg/kg iv day 1, capecitabine 650 mg/m 2 bid days 1-14, and gemcitabine 1000 mg/m 2 iv days 1 and 8; cycles repeated every 21 days. Among 50 patients, 1 patient achieved complete response (CR) (2%), 10 partial response (20%) and 30 stable disease (60%). Median PFS and OS were 5.8 and 9.8 months, respectively. Grade 3/4 toxicities included neutropenia 38%, thrombocytopenia 16%, thromboembolic events 14%, nausea 14%, hypertension 8%, and gastrointestinal bleeding 8%. One treatment-related death occurred (hemorrhage).
A phase I study of a chemotherapy doublet (gemcitabine plus capecitabine), combined with a biologic doublet (bevacizumab plus erlotinib) in patients with advanced pancreatic adenocarcinoma was presented at the annual meeting of ASCO, 2008 (the TARGET trial). 56 Patients with advanced (including locally advanced) carcinoma were treated at 4 cohorts of escalating capecitabine doses (days 1-21): 910 mg/m 2 , 1160 mg/m 2 , 1400 mg/m 2 and 1660 mg/m 2 . The doses of co-administered gemcitabine (1000 mg/m 2 days 1, 8 and 15), bevacizumab (5 mg/kg days 1 and 15), and erlotinib (100 mg/day) every 28 days were constant. Dose-limiting toxicity occurred in 1 patient at 910 mg/m 2 (grade 3 epistaxsis) and 2 patients at 1660 mg/m 2 (grade 3 diarrhea, and grade 3 skin rash for more than 7 days). No patient developed gastrointestinal perforation or pneumonitis, while a gastrointestinal bleed (grade 1) was seen in 1 patient. Among evaluable 14 patients, there were 5 confi rmed partial responses (36%) and a 50% decrease in CA 19-9 by 8 weeks was seen in 9 patients (64%). The maximal tolerable dose of capecitabine in this four-drug cytotoxic/biologic combination is 1660 mg/m 2 and a follow-on phase II study is planned. Kulke et al performed a phase II study of capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer. 57 Thirty patients with gemcitabine-refractory metastatic pancreatic cancer were treated with capecitabine, administered at a dose of 1000 mg/m 2 twice daily for 2 weeks, followed by a 1-week break. All patients also received erlotinib 150 mg daily. Treatment with capecitabine and erlotinib in gemcitabine-refractory patients was associated with an overall objective radiologic response rate of 10% and median survival duration of 6.5 months. In addition, 17% of the treated patients experienced decreases in tumor marker (CA 19-9) levels of more than 50% from baseline. Common toxicities included diarrhea, skin rash, fatigue, and HFS. This regimen may offer an acceptable treatment option in patients who experience treatment failure with standard fi rst-line therapy with gemcitabine.
Oral capecitabine has been used in pancreatic cancer as a radio-sensitizing agent. A phase I study done by Saif et al showed that capecitabine 800 mg/m 2 bid with concurrent external radiation therapy is feasible in patients with locally advanced pancreatic cancer. 58 This study was further confi rmed by a phase II study. 59 This approach offers an easy alternative to intravenous fl uorouracil as a radiosensitizer but more studies are needed to be done.
Capecitabine in anal cancer
Since 5-fl uorouracil (5-FU) + mitomycin C (MMC)-based chemoradiotherapy is standard treatment for patients with epidermoid anal carcinoma, a recent phase II trial determined the feasibility, toxicity, and effi cacy of capecitabine, MMC and radiotherapy (RT) in anal cancer patients. Radiotherapy comprised the schedule of the UK Anal Cancer Trial (ACT) II trial (50.4 Gy in 28 fractions of 1.8 Gy). 60 With MMC (12 mg/m 2 ) on day 1 and capecitabine on each RT treatment day in 2 divided doses (825 mg/m 2 bid). The endpoints were CR at 4 weeks, local control at 6 months and toxicity.
Thirty-one patients entered the trial. The median age was 61 years (range 45-86) with 14 males and 17 females. Compliance with chemotherapy with no dose interruptions or delays was 68%, and with RT was 81%. Eighteen (58%) patients completed both modalities of treatment as planned. Dose-limiting Grade 3 or 4 diarrhea was seen in 1 of 31 patients. Three patients experienced Grade 3 neutropenia. There were no treatment-related deaths. Four weeks following completion of chemoradiation, 24 patients (77%) had a complete clinical response and 4 (16%) a partial response. With a median follow-up of 14 months, 3 locoregional relapses occurred.
Capecitabine with MMC and RT in patients with anal carcinoma is well tolerated, with minimal toxicity and acceptable compliance. Further testing of this schedule in Phase III studies is undergoing.
Capecitabine in hepatobiliary cancers
Capecitabine is also actively in hepatobiliary tumors. Patt et al performed a retrospective analysis of all patients with hepatocellular carcinoma (HCC), cholangiocarcinoma (CCA), or gallbladder carcinoma (GBC) who were treated with oral capecitabine. 61 A total of 63 patients were treated with capecitabine (37 with HCC, 18 with CCA, 8 with GBC). Capecitabine 1000 mg/m 2 was administered twice daily for 14 days. Treatment was repeated every 21 days. Each patient received 1 to 15 treatment cycles. Nine (14%) to 11% of patients with HCC, 6% of patients with CCA, and 50% of patients with GBC had either a CR or a partial response. A CR was radiologically confi rmed in 1 patient with HCC and in 2 patients with GBC. The median survival times were 10.1 months (95% CI 4.5-15.7 months) for patients with HCC, 8.1 months (95% CI, 7.4-8.9 months) for patients with CCA, and 9.9 months (95% CI, 4.4-15.4 months) for patients with GBC. The most common toxicity was HFS (37%). Grade 3 thrombocytopenia occurred in 8% of patients with HCC.
No other signifi cant toxicities were observed. For all patients, response to treatment was positively correlated with survival and decline in tumor markers. The author concluded that capecitabine is safe for patients with hepatobiliary carcinoma, including those with cirrhosis. The antitumor activity of single-agent capecitabine was most pronounced in patients with GBC, was modest in patients with HCC, and was poor in patients with CCA.
The combination of capecitabine with platinum compounds as well as triplet has also been studied in small studies. [62] [63] [64] Worth-mentioning studies may include but are not limited to the FFCD 03-03 trial: a multicenter phase II trial of capecitabine plus oxaliplatin (XELOX); capecitabine plus cisplatin; and triplet of doxorubicin, cisplatin and capecitabine for metastatic hepatocellular carcinoma.
Discussion
Capecitabine is currently the only novel, orally homeadministered fluorouracil prodrug. Capecitabine could replace 5-FU either as a single agent or as the combination partner for chemotherapy or radiotherapy in nearly all gastrointestinal malignancies. It offers patients more freedom from hospital visits and less inconvenience and complications associated with infusion devices. The drug has been extensively studied in large clinical trials in many gastrointestinal and non-gastrointestinal malignancies, and compares favorably with fl uorouracil with a safe toxicity profi le, consisting mainly of gastrointestinal and dermatologic adverse effects. Whereas gastrointestinal events and HFS occur often with capecitabine, the tolerability profi le is comparatively favorable. Prompt recognition of severe adverse effects is the key to successful management of capecitabine.
Ongoing and future clinical trials will continue to examine, and likely expand, the role of capecitabine as a single agent and/or in combination with other anticancer agents for the treatment of other solid tumors, both in the advanced palliative and adjuvant settings.
It is important to appreciate that the combination of capecitabine with agents such as irinotecan and oxaliplatin is more than just replacing the backbone of 5-FU. There is a molecular rationale: XELIRI → capecitabine inhibits Bcl-2, a protein that prevents tumor cell death (apoptosis) by radiation, taxanes, oxaliplatin and irinotecan, and XELOX → capecitabine inhibits ERCC-1, a DNA repair protein that blocks the cytotoxic activity of radiation and oxaliplatin. In addition, irinotecan and oxaliplatin induce TP in tumors. Similarly, our group has also investigated the effect of radiation on TP and showed that radiation upregulates TP in tumors, but not in normal cells. This combined modality then synergizes in both directions: radiation as chemosensitizer by upregulating TP and capecitabine after conversion to 5-FU radiosensitizing the tumor to radiation effects. This combination is of utmost interest in clinical investigation in many tumors, especially rectal cancer.
It is also important to appreciate that dose reductions in pivotal studies in colorectal cancer indicated that dose reduction did not reduce the effi cacy of capecitabine. 65 Currently, 2500 mg/m 2 is the FDA-approved dose of capecitabine but this dose is not tolerated by patients in the US. Another issue related to the dose is the two different strengths of capecitabine (150 and 500 mg). Some physicians prefer to prescribe the dose with 500 mg capsules only to prevent any overdose or underdose by a patient. We also suggest that the dose should be rounded to the closest fi gure to make a dose that contains a similar strength of capecitabine capsules for convenience and to decrease the risk as noted above.
One interesting observation was recently published by Hennig et al 66 who compared overall acceptability to patients between intravenous FU/LV or oral capecitabine. Patients scheduled for adjuvant single-agent fl uoropyrimidine therapy were randomly assigned to receive once-weekly FU/LV (425 mg/m 2 FU, 45 mg LV) for 6 weeks, followed by two 3-week cycles of capecitabine (1250 mg/m 2 twice daily, days 1 through 14), or the same treatments but in reverse order. After 12 weeks, the patients were asked which treatment they preferred, and received the preferred treatment for an additional 12 weeks. The primary end point was patient preference. After 40 of the planned 74 patients had been randomly assigned, real-time adverse event monitoring led to early trial closure because of excess sequence-specifi c toxicity. In chemotherapy-naïve patients, capecitabine produced more toxicity than FU/LV, but at levels in line with previously reported data. However, treatment with capecitabine after FU/LV caused markedly increased toxicity, indicating a sequence-specifi c interaction as shown in Table 2 . The mechanism has not been determined, but interaction with intracellularly retained folate after FU/LV therapy is a possibility. Oncologists need to be aware of this risk if considering crossing patients over from FU/LV to capecitabine-based regimens.
Education of the patient and the caretaker is paramount in management of capecitabine toxicity. There are several drug interactions with capecitabine and the patient must be educated to prevent adverse outcomes. Data on patients with DPD defi ciency and tolerance of capecitabine are scarce. 67 We suggest that it is still important to suspect and test for DPD defi ciency in patients on capecitabine with any manifestation of toxicity.
Summary
In summary, most current data indicate that capecitabine is not inferior to infusional 5-FU and offers added benefi t of convenience. Future studies should also aim at evaluating the drug cost. For those parts of the world in which hospitalization is required to deliver fl uorouracil by infusion, an outpatient oral regimen has an advantage. Capecitabine offers not only effi cacy in different gastrointestinal and non-gastrointestinal malignancies, but also broadens the availability and convenience of treatment. 
